General Updates
- Q1 FY27 net profit surged 211% YoY to ₹33.91 Cr, delivering 75% of the prior full-year TTM profit in a single quarter.
- Strategic pivot from commodity dye intermediates toward high-margin regulatory pharma molecules (MCP exports to Japan targeting $4,000/kg) and specialty chemicals.
- Commissioning of 7 MW / 32 MW solar power capacity reducing power costs and supporting operating margins.
- Virtually debt-free balance sheet (D/E 0.01, debt ₹8 Cr) combined with high promoter ownership (71.8%).
- Potential quarter-to-quarter earnings lumpiness if pharma export deliveries are batch-based.
- Cyclicality and supply-demand imbalances in legacy merchant dye intermediate products.
- Raw material price volatility impacting chemical gross margins.
Executive Summary
Bhageria Industries reported an exceptional Q1 FY27 earnings performance, with consolidated net profit surging 211.7% YoY to ₹33.91 Cr (EPS ₹7.83 vs ₹2.58 YoY). In a single quarter, the company generated ~75% of its entire prior TTM PAT (₹45 Cr). Revenue rose 84.2% YoY to ₹302.03 Cr. This earnings breakout validates the strategic transition from commodity dye intermediates into high-margin regulatory pharma intermediates (e.g., MCP targeting Japan export markets) and process-integrated solar power generation.
Earnings Ramp-Aware Impact Math
- Baseline TTM Position (FY26): TTM Revenue = ₹874 Cr, TTM PAT = ₹45 Cr, TTM EPS = ₹10.55.
- Q1 FY27 Actuals: Revenue = ₹302.03 Cr, PAT = ₹33.91 Cr, Quarterly EPS = ₹7.83.
- Annualized Run-Rate: Annualized PAT = ₹33.91 Cr * 4 = ₹135.6 Cr (EPS ₹31.3).
- Base Case Projection (FY27E): Factoring in potential quarter-to-quarter variability, assuming conservative full-year PAT of ₹115 Cr (EPS ₹26.5, up ~150% YoY).
- Valuation Re-rating: At a modest forward P/E of 15x on base EPS of ₹26.5, target price = ₹397.5 (74% upside over ₹228.1 as-of price).
Industry & Capital Intensity
- Capital Intensity: MEDIUM. Planned capacity expansions (adding ₹50-75 Cr revenue) and 32 MW solar power capacity are largely commissioned with minimal debt burden (D/E 0.01).
- Execution Difficulty: MEDIUM. Transitioning to regulatory markets (e.g. Japan) requires strict quality compliance, but high existing plant utilization (95%) proves strong operational execution.
Scenario Analysis
- Base Case (+75%): FY27 PAT reaches ₹115 Cr (EPS ₹26.5). Valued at 15x P/E -> Target Price ₹398.
- Bull Case (+135%): Q1 margin expansion sustains; full year PAT reaches ₹130 Cr (EPS ₹30.0). Re-rating to 18x P/E -> Target Price ₹540.
- Bear Case (-20%): High margins prove temporary due to batch order timing; PAT normalizes to ₹40 Cr (EPS ₹9.2). At 20x trailing P/E -> Target Price ₹184.
Verdict Rationale
Bhageria presents a textbook earnings inflection candidate with structural fundamental backing: zero debt, 71.8% promoter ownership, expanding ROCE, and clear execution of high-value pharma/specialty strategy. Rated as a STRONG_CANDIDATE.
